Cargando…
Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report
BACKGROUND: Uterine leiomyosarcoma (uLMS) is a rare tumor that accounts for 1% of all uterine malignancies. In spite of adequate surgical resection of uLMS, even in the early stage, patients remain at high risk for local and distant recurrence. Therefore, the treatment of advanced uLMS represents a...
Autores principales: | Nteli, Viktoria-Anna, Knauf, Wolfgang, Janton-Klein, Anja, El-Safadi, Samer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836215/ https://www.ncbi.nlm.nih.gov/pubmed/29515415 http://dx.doi.org/10.1159/000486638 |
Ejemplares similares
-
Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report
por: Bongiovanni, Alberto, et al.
Publicado: (2015) -
Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin
por: Amant, Frédéric, et al.
Publicado: (2015) -
Long lasting response of trabectedin in patient with gastric leiomyosarcoma with liver metastasis: an update to previous report
por: Rastogi, Sameer, et al.
Publicado: (2019) -
Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma
por: Tansir, Ghazal, et al.
Publicado: (2020) -
Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline
por: Maruzzo, Marco, et al.
Publicado: (2016)